Continued from page 1

Meanwhile, others slammed Novartis for its decision to go to the courts.

“Companies like Novartis should not be in the position to block moves to more cost-effective treatments in order to maximize their profits,” said John Harris, of the Institute for Science Ethics and Innovation at the University of Manchester, in a statement. He said it was legitimate for health providers to use treatments that were much cheaper than ones that were already licensed.

Genentech developed both Avastin and Lucentis, but Novartis has exclusive rights on Lucentis outside the U.S.